Speakers
Leila Abbas, Preclinical Lead, Rinri Therapeutics
Elsa Abranches, Chief Scientific Officer, ViSync Technologies
Michael Aigner, Head of Manufacturing / QP, University Hospital Erlangen
Nicola Ambler, Founder, The CGT Circle
Claudia Andretta, Strategic Advisor, Sichem Bio
Mohamed Awwad, Group Leader, Heidelberg University Hospital
Owen Bain, Director/Qualified Person, Cell & Vector Innovation Centre, Royal Free London NHS Foundation Trust
Kiren Baines-Mortimore, CEO and Co-Founder, Valaya Bio
Christopher Ballas, Global Commercial Lead, Custom Cell Products, Cook MyoSite Inc
Ricardo Baptista, Chief Technology Officer, Smartcella
Samantha Barber, Chief Executive Officer, Gene People
Roy Baynes, Executive Vice President and Chief Medical Officer, Eikon Therapeutics
Gaurav Bhavsar, Technical Director GTVF, Gene Therapy Vector Facility, Kings College London
Jaap Jan Boelens, Chief, Transplantation and Cellular Therapies, Memorial Sloan-Kettering Cancer Center
Pedro Borga, Regional Market Access and Pricing Director, Amicus Therapeutics
Jonathan Bracey, Founder, MVA Society
Hugh JM Brady, Professor of Immunology, Imperial College London
Simon Briggs, Director Advanced Analytics, Orchard Therapeutics Ltd
Mike Broeders, Advisor, FAST (Future Affordable Sustainable Therapies)
Henriette Burghoorn, Associate Director, Market Access, Gilead Sciences
Lara Campana, SVP, Head of Research and Translational Science, Resolution Therapeutics
Aline Charpentier, Science Strategy and Innovation Lead, Wellcome Genome Campus
Hester Chu, Research Assistant, Neurodegenerative Diseases, ucl
Matthew Cobb, Independent Consultant, Hoya Consulting
Randolph Corteling, Chief Scientific Officer, ReNeuron
Matthieu Coutet, Partner, Sofinnova Partners
Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Hannah Crocker, Advanced Therapies Outcomes Manager, NHS Wales Joint Commissioning Committee (NWJCC)
Davide Danovi, Independent Partner, Hoya Consulting
Marc de la Roche, Asst. Professor, Dept. of Biochemistry, University of Cambridge
Simon de Miquel, Strategic Project Manager at the Advanced Therapies Platform, Sant Joan de Déu Hospital
Padraig Donlon, Analytical Development Research Scientist, Autolus
James Duboff, Strategic Partnerships Director, Genomics England
Beatriz Duran, Consultant Pharmacist and Head of Clinical Trials Pharmacy Service and ATMPs, Manchester University NHS Foundation Trust
Omer Dushek, Professor of Molecular Immunology, University of Oxford
Mark Eccleston, CEO, ValiRx
Mark Exley, CSO, LIfT Biosciences
Katherine Forsey, Chief Research Officer, Charcot Marie Tooth Association
Miguel Forte, CEO, Kiji Therapeutics and President, International Society of Cell and Gene Therapy, Kiji Therapeutics
Daniel Fowler, Research Fellow, ucl
Natalie Francis, Head of Process Development, King's College London
George Frodsham, Founder & CEO, MediSieve Limited
Ashleigh Furlong, Health reporter, Bloomberg News
Toby Gamlen, Head of Manufacturing, Gene Therapy Innovation and Manufacturing Centre, University of Sheffield
Oscar Garcia, Postdoctoral Fellow, BOKU University
Ibon Garitaonandia, Chief Scientific Officer, CellProthera
Bobby Gaspar, Chief Executive Officer, Orchard Therapeutics
Bernd Giebel, Professor, University Hospital Essen
Mo Girach, Honorary Fellow, University of Buckingham
Paul Gissen, Clinical Professor of Paediatric Metabolic Medicine, UCL Great Ormond Street Institute of Child Health
Janet Glassford, Expert Quality Assessor, Biologicals Unit, Medicines & Healthcare products Regulatory Agency
Steffen Goletz, Professor, Department of Biotechnology and Biomedicine, Danish Technical University
Brad Groves, Director, NICE Advice, National Institute for Health & Care Excellence (NICE)
Nagy Habib, Professor of Surgery, Imperial College London
Killian Hanlon, CEO, Lir Therapeutics
Rafiq Hasan, CEO, Complement Therapeutics
Lyn Healy, Visiting Scientist, King's College London
Dr Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan
Christian Hill, Board Member, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Lilian Hook, Director of Cell, Apheresis and Gene Therapies, NHS Blood and Transplant
Patrick Hopkinson, Independent HTA Expert, Independent HTA Expert
Simon Howell, Professor, KCL
Marit Inngjerdingen, Professor, University of Oslo
Melita Irving, Group Leader, University of lausanne
Mark Isalan, Professor of Engineering Biology, Imperial College London/ Toggle Therapeutics
Dr Sheba Jarvis, Consultant Endocrinology, Imperial College London
Aleck Jones, CEO, Co-founder, Kindling Bio
Olivier Gerrit de Jong, Assistant Professor, Utrecht University
Margareth Jorvid, Board Member, Elicera Therapeutics
Andrew Joseph, Europe Correspondent, STAT
Manel Juan, Immunologist, Hospital Clínic de Barcelona
Anastasios Karadimitris, Professor, Langmuir Chair in Haematology and Consultant Haematologist, Imperial College London
Sophia N Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy, King's College London
Tina Karapouliou, Research Fellow, UCL GOS ICH
Rajvinder Karda, Professor in Gene Therapy, Institute for Women’s Health, University College London
Cornelia Kasper, Head of Institute for Cell and Tissue Culture Technologies, University Of Natural Resources And Life Sciences Vienna
Gaik Sui Kee, Director, Vector Development, Orchard Therapeutics
Rahul Khetan, Venture Associate, UCB Ventures
Sven Kili, Partner, Saisei Ventures
Janine Kirby, Professor, University of Sheffield
Semra Kitchen, Senior Director, Search & Evaluation, R&I, AstraZeneca
Anna Koptina, CEO, Exellerium
Mathias Kroll, Chief Business Officer, Cynata Therapeutics Ltd
Gray Kueberuwa, CEO, ImmunoKey
Dimitri Kullmann, Professor of Neurology, University College London (UCL)
Parag Kumthekar, Lead Gene Therapy Downstream Process Development, UCB
Dinesh Kundu, CEO, East Ocyon Bio Pvt. Ltd.
David Kuntin, CEO, Mesenbio
Jon Amund Kyte, Head of Department for Clinical Cancer Research, University of Oslo, Oslo University Hospital
Amelia Lane, Director Preclinical Development, MeiraGTx
Bastiaan Leewis, SVP MSAT, MeiraGTx
Roger Legtenberg, Co-Founder & Managing Partner, Partners4Patients Foundation
Sarah Leonard, Interim Chief Executive Officer, T-Cypher Bio
Giulia Leonetti, Policy Officer, European Commission
James Levine, President, Fondation Ipsen
Eleuterio Lombardo, Former Director of Cell Therapy Characterization & Development, Cell Therapies, Takeda
Mark Lowdell, CSO, INmuneBio
Àngel Lucio Pereira, CEO, Tetraneuron
Alejandro Madrigal, OBE FMedSci, Professor of Haematology, UCL Cancer Institute
Alessandra Magnani, Head of the advanced therapies and immunotherapy platform, Hospital Sant Joan de Déu Barcelona
Heather Main, Co-Founder, Hoya Consulting
Harris Makatsoris, Professor of Manufacturing, King's College London
Salah Mansour, Associate Professor in Cellular Immunology, University of Southampton
Marc Martinez-Llordella, Founder and VP Biology, Quell Therapeutics
Marjolein Meinders, Co-Founder, Scarlet Therapeutics
Laurie Menger, Advanced T-cell Therapy group leader, Gustave Roussy/INSERM
Anton Van der Merwe, Professor of Molecular Immunology, University of Oxford
Jose Meseguer Ripolles, Head, Translational Digital and Data Science, Resolution Therapeutics
Anji Miller, Skills Lead, Innovation Hubs for Gene Therapies/Programme Director, Translational Skills, LifeArc
Manal Mohammed, Associate Professor, University of Westminster
David Morrow, Scientific Lead for Advanced Therapies, EATRIS
Mustafa Munye, VP Operations, Complement Therapeutics
Darren Nesbeth, Associate Professor, University College London
Sara Nolbrant, Director, Pre-GMP Facility, Lund Stem Cell Center
Daniel O'Connor, Director, Regulatory Policy & Early Access, ABPI
Raphael Ognar, President & CEO, Co-founder, NKILT Therapeutics Inc.
Dilip Patel, SVP Global Pricing and Market Access, Autolus
Tanya Patel, Senior Manager CTSM, BioNTech
Tom Payne, Chief Operating Officer, Laverock Therapeutics
Devin Peipert, Professor of Health Outcomes Measurement, University of Birmingham
David Peritt, Chief Scientific Officer, Lupagen
Carolina Pola, CEO, Stab Therapeutics
Pilar Redondo, Site Head Madrid, Cell Therapy Technology Center, Takeda
Nicola Robertson, Professor of PerinatalProfessor of Perinatal Neuroscience & Consultant in NeonatologyNeuroscience, UCL
Andrew Roddam, Founder & Principal, Cibola Life Sciences Ltd
Ali Roghanian, Associate Prof in Cancer Immunotherapy, University of Southampton
Anne Rosser, Professor of Clinical Neurosciences, Cardiff University
Ulrich Ruemenapp, Senior Biotech Program Lead, Bayer AG
Tara Sadeghi, Chief Operating Officer, Cellenkos Inc.
Moin Saleem, Founder & CSA, Purespring Therapeutics
Ilves Sanna, Head of Pharmacy Clinical Trials & Aseptic Services, The Royal Marsden NHS Foundation Trust
Giorgia Santilli, Associate Professor in Gene Therapy, UCL Great Ormond Street Institute of Child Health
Vlad Seitan, Chief Scientific Officer, Laverock Therapeutics
Marta Serafini, Associate Professor, School of Medicine and Surgery, University of Milano-Bicocca
Lior Shaltiel, Chief Executive Officer, NurExone Biologic
Ricardo Silva, Senior Scientist, iBET: Instituto de Biologia Experimental e Tecnológica
Chrysanthi Sitmalidou, Senior Scientist, Orchard Therapeutics
Jan Spanholtz, Chief Scientific Officer, Glycostem Therapeutics
Jonathan Sumner, Associate Principal Scientist, AstraZeneca
Marina Tarunina, Research Director, Plasticell
Kayleigh Thirlwell, Sr Director, Resolution Therapeutics
Samantha Thomas, Head of Research, ReNeuron
Ash Toye, Professor of Cell Biology, University of Bristol & Co-founder, Scarlet Therapeutics, University of Bristol
Pamela Tranter, Head, Translational Research Group (TRO), University College London
Kristian Tryggvason, Chief Executive Officer, Alder Therapeutics
Piotr Trzonkowski, CEO, PolTREG
Sheela Upadhyaya, Life Science Advisor and Founder, Rarely Ordinary
Anton Ussi, CEO, EATRIS ERIC
Sachin Vadgama, Director of HEOR, Multiple Myeloma, Gilead
Frederick Vonberg, Neurology Registrar, University College London Hospitals NHS Foundation Trust
Arsalan Wafi, Academic Clinical Lecturer in Vascular Surgery, King's College London
Mary Wang, Director, Patient Engagement, Genespire
Ben Weil, Chief Operating Officer & Chief Manufacturing Officer, INmuneBio
Darius Widera, Professor of Stem Cell Biology and Research Division Lead, University of Reading
Keith Wilson, Director, South Wales Blood and Marrow Transplant Programme, Cardiff and Vale University Health Board
Jörg Wischhusen, Professor, Universitätsklinikum Würzburg
Andrew Zambanini, Head of Innovative Therapies, Innovation Accelerator, MHRA
Nan Zhang, Chief, Cell Therapy Manufacturing Section, Center for Cellular Engineering, National Institutes of Health
Cem Zorlular, CEO, Er-Kim Pharmaceuticals
Bobby Zubis, Senior Director of Strategy & Operations, Resolution Therapeutics Ltd
Get Involved with Advanced Therapies Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events